Protagonist Therapeutics (PTGX) Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/25/2026

1. QCOM
2. MU
3. FDX
4. CBRS
5. USO
6. HTZ
7. SPY
8. KBH
9. HON
10. GOOGL

Go back to Protagonist Therapeutics (PTGX) Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
(NASDAQ: PTGX) Delayed: 122.15 +3.19 (2.68%)
Previous Close $118.96    52 Week High $24.52 
Open $119.38    52 Week Low $10.02 
Day High $124.80    P/E N/A 
Day Low $118.81    EPS $0.00 
Volume 1,132,431